Xilio Therapeutics, Inc. (NASDAQ:XLO) Sees Large Increase in Short Interest

Xilio Therapeutics, Inc. (NASDAQ:XLO) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 396,100 shares, a growth of 278.0% from the October 15th total of 104,800 shares. Currently, 1.9% of the company’s stock are sold short. Based on an average trading volume of 252,700 shares, the short-interest ratio is currently 1.6 days.

Institutional Investors Weigh In On Xilio Therapeutics

A hedge fund recently raised its stake in Xilio Therapeutics stock. Renaissance Technologies LLC grew its holdings in Xilio Therapeutics, Inc. (NASDAQ:XLO) by 18.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 295,000 shares of the company’s stock after acquiring an additional 45,554 shares during the period. Renaissance Technologies LLC owned about 0.80% of Xilio Therapeutics worth $280,000 at the end of the most recent quarter. 54.29% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Raymond James lowered their target price on shares of Xilio Therapeutics from $6.00 to $4.00 and set an “outperform” rating for the company in a research note on Friday, November 8th.

Xilio Therapeutics Stock Performance

Shares of XLO opened at $1.00 on Thursday. The stock has a 50-day moving average of $0.89 and a two-hundred day moving average of $0.95. The stock has a market cap of $43.85 million, a P/E ratio of -0.58 and a beta of -0.24. Xilio Therapeutics has a one year low of $0.49 and a one year high of $1.93.

Xilio Therapeutics Company Profile

Xilio Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery and development of tumor-activated immuno-oncology therapies. The company’s checkpoint inhibitor program includes XTX101, an investigational Fc-enhanced, tumor-activated anti-CTLA-4 mAb that is in Phase 2 clinical trial for patients with advanced solid tumors.